The Web site of the student-run Harvard Health Policy Review is up and running after about a week of mysterious down time, and the journal's editor has apologized for running a controversial article without proper bias screening. linkurl:Rumors;http://www.gooznews.com/archives/001223.html circulated last week when the Review Web site was down that Harvard authorities had censored the publication of the article, which addressed a long-standing debate about the total cost for developing a drug, from the spring 2008 issue. The article, written by linkurl:Donald Light;http://sph.umdnj.edu/staff/staffDetail.cfm?tblPers_ID_pk=564 of the University of Medicine & Dentistry of New Jersey and linkurl:Rebecca Warburton;http://publicadmin.uvic.ca/faculty/warburton/index.htm of the University of Victoria, describes the authors' difficulty in publishing a critique of another article, which estimated drug development costs at $802 million and was published in 2003 in the Journal of Health Economics (JHE) by linkurl:Joseph DiMasi;http://csdd.tufts.edu/About/ResearchStaff.asp at Tufts Center for the Study of Drug Development. (For more background on the...
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?